Viatris Reports Second-Quarter 2026 Financial Results
Viatris (Nasdaq: VTRS) reported Q2 2026 total revenues of $3.8B, up 5% reported and 3.5% operationally vs. Q2 2025, with U.S. GAAP net loss of $119M. Adjusted EBITDA was $1.2B. The company raised 2026 guidance midpoints, reduced gross leverage to 2.9x, returned about $550M via buybacks, and noted FDA approval of Gwyn LoTM and sale of Tyrvaya rights.
How this was made
The 30-second read
Why it matters
Traders can update valuation and positioning based on the raised 2026 guidance midpoints, leverage reduction to 2.9x, and near-term catalysts from FDA approval and the Tyrvaya rights transaction, while monitoring second-half supply disruption risk.
Market read
This is a multi-catalyst earnings release with guidance raise and concrete regulatory and deal updates, which typically drives immediate repricing and near-term trading volume.
What to watch
The guidance excludes certain transaction and restructuring costs, and the article flags intermittent manufacturing disruptions and expected revenue impact of $100M to $150M in 2H 2026, which may be underweighted by the market.
Background
Viatris released its second-quarter 2026 financial results and bundled them with pipeline, regulatory, and portfolio actions (FDA approval, Tyrvaya rights sale, and capital return).
Ticker impact
Viatris reported Q2 2026 results, raised 2026 guidance midpoints, and disclosed Tyrvaya rights sale plus FDA approval of Gwyn LoTM.
Bias to upside on guidance raise and FDA approval, partially offset by the larger GAAP net loss tied to the Tyrvaya intangible write-down.
The article contains multiple fresh, decision-relevant disclosures: Q2 financials, leverage reduction, capital return, a definitive Tyrvaya rights sale agreement, and an FDA approval with expected commercial availability later in 2026. GAAP loss is negative, but adjusted metrics and guidance raise are supportive.
Market effects
Signals continued capital rotation and pipeline progress in large-cap generic and specialty pharma, potentially supporting sentiment toward peers with similar monetization and FDA catalysts.
Greater China growth cited as a driver, which can influence regional demand expectations for branded and generics portfolios.
FDA approvals and rights monetization underscore ongoing regulatory and portfolio-management dynamics that can affect global pharma supply and licensing markets.
Counterpoint
GAAP net loss widened materially due to a non-cash Tyrvaya-related charge, and supply disruptions are expected to pressure second-half revenues, which could limit upside despite guidance midpoint raises.
Key entities
- companyViatris Inc.
Reported Q2 2026 financial results, raised 2026 guidance midpoints, and announced Tyrvaya rights sale and FDA approval of Gwyn LoTM.
- companyHarrow, Inc.
Named buyer for Viatris' global Tyrvaya product rights under a definitive agreement.
- regulatorU.S. Food and Drug Administration (FDA)
Approved Viatris' Gwyn LoTM and generic ferric carboxymaltose, and assigned a PDUFA goal date for MR-107A-02.
